1 October 2018 - The October 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are several major new listings this month:

• Eltrombopag olamine (Revolade) - new indication
  
• Nintedanib esylate (Ofev) - new medicine
  
• Omalizumab (Xolair) - new indication
  
• Ruxolitinib phosphate (Jakavi) - new medicine
  
• Sacubitril with valsartan (Entresto) - new combination product
  
• Secukinumab (Cosentyx) - new medicine
  
• Tacrolimus monohydrate (Tacrolimus Sandoz) - new indication
  
• Vildagliptin (Galvus) - new medicine
  
• Vildagliptin with metformin hydrochloride (Galvumet) - new combination product
  

Read New Zealand Pharmaceutical Schedule update